Last updated on November 2019

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Brief description of study

A national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in women and men with HR+, HER2-negative advanced or metastatic breast cancer

Clinical Study Identifier: NCT03096847

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.